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fetal GROwth restriction: deVeloping Endpoints: the
COSGROVE study
Patricia Healy, PhD; Sanne J. Gordijn, MD; Wessel Ganzevoort, MD; Irene M. Beune; Ahmet Baschat, MD;
Asma Khalil, MD; Louise Kenny, MD; Frank H. Bloomﬁeld, MD; Mandy Daly; Jamie Kirkham, PhD;
Declan Devane, PhD1; Aris T. Papageorghiou, MD1
BACKGROUND: Fetal growth restriction refers to a fetus that does not clusion in the core outcome set at a face-to-face meeting with 5
reach its genetically predetermined growth potential. It is well-recognized
that growth-restricted fetuses are at increased risk of both short- and long-
term adverse outcomes. Systematic evaluation of the evidence from
clinical trials of fetal growth restriction is often difficult because of variation
in the outcomes that are measured and reported. The development of core
outcome sets for fetal growth restriction studies would enable future trials
to measure similar meaningful outcomes.
OBJECTIVE: The purpose of this study was to develop core outcome
sets for trials of prevention or treatment of fetal growth restriction.
STUDY DESIGN: This was a Delphi consensus study. A compre-
hensive literature review was conducted to identify outcomes that were
reported in studies of prevention or treatment of fetal growth restriction.
All outcomes were presented for prioritization to key stakeholders (135
healthcare providers, 68 researchers/academics, and 35 members of
the public) in 3 rounds of online Delphi surveys. A priori consensus
criteria were used to reach agreement on the final outcomes for in-Cite this article as: Healy P, Gordijn SJ, Ganzevoort W,
et al. A Core Outcome Set for the prevention and treat-
ment of fetal GROwth restriction: deVeloping Endpoints:
the COSGROVE study. Am J Obstet Gynecol
2019;221:339.e1-10.
0002-9378
ª 2019 The Authors. Published by Elsevier Inc. This is an
open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
https://doi.org/10.1016/j.ajog.2019.05.039healthcare providers, 5 researchers/academics, and 6 maternity service
users.
RESULTS: In total, 22 outcomes were included in the final core outcome
set. These outcomes were grouped under 4 domains: maternal (n¼4),
fetal (n¼1), neonatal (n¼12), and childhood (n¼5).
CONCLUSION: The Core Outcome Set for the prevention and treat-
ment of fetal GROwth restriction: deVeloping Endpoints study identified a
large number of potentially relevant outcomes and then reached
consensus on those factors that, as a minimum, should be measured and
reported in all future trials of prevention or treatment of fetal growth re-
striction. This will enable future trials to measure similar meaningful
outcomes and to ensure that findings from different studies can be
compared and combined.
Key words: core outcome, fetal growth restriction, gestational age,
pregnancy, trialetal growth restriction (FGR) is aF condition of suboptimal growth of
the fetus in utero with heterogeneous
causes. It is associated with increased
risks of perinatal morbidity and death
and includes fetal hypoxia, birth
asphyxia, prematurity, stillbirth, and
neonatal death.1,2 Long after birth with
FGR, this group of infants is at higher
risk of poor growth, metabolic and car-
diovascular disorders, and neuro-
developmental delay.3,4 The scientiﬁc
community has undertaken detailedresearch into the causes, consequences,
prediction, and prevention of FGR.
However, these efforts have been
impeded by a lack of consensus on the
diagnosis of FGR: what exposure vari-
ables should be measured and what
outcomes collected.5 Thus, although
interventions for the prevention and
treatment of FGR have been studied,
the resulting evidence is often difﬁcult
to interpret because of differences in
inclusion, case selection, deﬁnitions, and
reporting of outcomes. Such heteroge-
neity results in difﬁculties not only of
direct comparisons between studies
but also renders the aggregation of
data among trials difﬁcult. This
means that evidence synthesis and
metaanalysis is unsatisfactory, which in
turn limits the reliability of evidence
to guide healthcare decisions.
These challenges could be mitigated
if it were possible to agree, in
advance, about which study data
should be collected. We previously
have reported on a consensusOCTOBER 2019 Ameriprocedure for the antenatal diagnosis
of FGR,6 the diagnosis of FGR in the
newborn period,7 and a minimum
reporting set of study variables for
FGR research studies.8 In this study,
we aimed to develop consensus
among international stakeholders on
a set of core outcomes that should be
used in trials that evaluate (1) pre-
ventative or (2) therapeutic in-
terventions for FGR. Core outcome
sets (COSs) represent an agreed
standard set of outcomes that should
be measured and reported, as a
minimum, in all clinical trials in
speciﬁc areas of healthcare; they are
also suitable for use in cohort studies,
clinical audits, and other research
methods.9 By standardizing a mini-
mum set of outcomes across trials,
the potential for evidence synthesis is
maximized, which improves the efﬁ-
ciency of trials, minimizes research
waste and reporting bias, and ulti-
mately ensures that evidence is readily
available for policy and practice.can Journal of Obstetrics& Gynecology 339.e1
AJOG at a Glance
Why was this study conducted?
Systematic evaluation of the evidence from clinical trials is often difﬁcult because
of variation in the outcomes that are measured and reported. The development
and implementation of core outcome sets for use in clinical trials improves the
efﬁciency of trials, minimizes research waste and reporting bias, and ultimately
ensures that evidence is readily available for policy and practice.
Key ﬁndings
The COSGROVE study identiﬁed 22 outcomes that are grouped under 4 domains
(maternal [n¼4], fetal [n¼1], neonatal [n¼12], and childhood [n¼5]) that
should be measured and reported in all future trials of prevention or treatment of
fetal growth restriction.
What does this add to what is known?
This core outcome set for fetal growth restriction will enable future trials to
measure similar meaningful outcomes and ensure that ﬁndings from different
studies can be compared and combined.
Original Research OBSTETRICS ajog.orgMethods
The protocol of the COSGROVE study
(Core Outcome Set for GROwth re-
striction; deVeloping Endpoints) is
described in detail elsewhere.10 In brief,
to build consensus from relevant stake-
holders, a systematic review of outcomes
was ﬁrst conducted to identify all po-
tential outcomes that are collected in
studies of FGR. After this, the outcomes
that were identiﬁed were presented to
stakeholders for prioritization in a
modiﬁed Delphi study. Finally, the
prioritized list of outcomes was dis-
cussed in a face-to-face meeting, and a
consensus was reached on which out-
comes would be included in the ﬁnal
COS. Two separate procedures were
conducted initially (1 for prevention and
another for treatment of FGR); however,
the results from these separate consensus
procedures were almost identical and
suggested that combining the 2 was
appropriate; therefore, a single COS was
created.
The design was guided by the Core
Outcome Set-STAndards for Develop-
ment (COS-STAD).11 We report the
ﬁndings of the COSGROVE study in
accordance with the Core Outcome
SeteSTAndards for Reporting Statement
COS-STAR12 and guidance from Core
Outcome Measures in Effectiveness Tri-
als Initiative.13 The study was registered339.e2 American Journal of Obstetrics& Gynecolprospectively with the Core Outcome
Measures in Effectiveness Trials initiative
(registration number 689, available on-
line at http://www.comet-initiative.org/
studies/details/689/).
Identification of relevant outcomes
We conducted a comprehensive search
of the published literature that included
previous trials and systematic reviews of
trials to identify potential outcomes. We
searched the Cochrane Central Register
of Controlled Trials, EMBASE, and
Medline from inception to June 2017 for
randomized controlled trials and sys-
tematic reviews that evaluated any po-
tential intervention for the prevention or
treatment of FGR. The review high-
lighted a signiﬁcant lack of standardiza-
tion in what outcomes are measured and
reported. The outcomes from this review
were grouped into the following do-
mains: maternal, fetal, neonatal, child-
hood, and patient-reported quality of
life, with subcategories as appropriate.
Participants
To reﬂect the perspectives of a variety of
international stakeholders with
informed opinions or known expertise
in FGR, we accessed potential partici-
pants through mass invitational emails,
electronic discussion lists, professional
organizations, and social media. Toogy OCTOBER 2019capture as broad a ﬁeld of expertise as
possible, invitees were encouraged to
forward the invitation to others whom
they regarded as having appropriate
experience. We used purposeful sam-
pling to approach 8 groups of stake-
holders: (1) users of maternity services
(women and their partners) or their
representative advocacy group, (2) mid-
wives, (3) obstetricians, (4) pediatri-
cians/neonatologists, (5) family doctors,
(6) ultrasonographers, (7) policy
makers, and (8) individuals with speciﬁc
expertise/interest in research or perinatal
care related to FGR. These groups were
later combined into 3 groups: healthcare
providers; researchers/academics, and
maternity service users. This was done
to present ﬁndings by stakeholder
groups in the Delphi Manager platform
(http://www.comet-initiative.org/delphi
manager/), which was used for the COS
development. We provided potential
participants with an explanatory email
and a video (https://youtu.be/
yqAvHJcs2Rg) that outlined the need
for the study, the principles of a COS,
and the participant involvement. In-
dividuals who wished to participate were
then asked to click on a link to register
for the study and indicate their consent
to receive the Delphi survey.
Ethical approval for the study was
obtained from theMedical Ethics Review
Committee of the University of
Groningen.
Modified Delphi study
We conducted a 3-round modiﬁed Del-
phi study using the web-based Delphi-
Manager system (http://www.comet-
initiative.org/delphimanager/). Each
round had a response closing date 21
days after the date of distribution of the
survey, with regular email reminders to
nonresponders. A short questionnaire
that sought relevant participant de-
mographic data that included stake-
holder group and country of residence
was presented in the ﬁrst round.
The round 1 survey presented the
outcomes identiﬁed in the review. Each
outcome was explained in plain English
with explanations from patient infor-
mation leaﬂets where available. Partici-
pants were asked to rate each outcome
ajog.org OBSTETRICS Original Researchfor FGR prevention and treatment
separately on a 9-point Likert-scale, with
higher values representing increased
importance for inclusion in the COS, or
to select an “unable to score” category.
Participants were given the option to add
up to 2 further “new” outcomes that they
considered important or relevant for
inclusion in COS.13 Only participants
who had completed the ﬁrst round were
invited to participate in round 2.
The round 2 survey presented all
outcomes from round 1. In round 2, in
addition to presenting each participant’s
individual round-1 score, results for
each separate stakeholder group were
also presented numerically as pro-
portions. Using the same 9-point Likert
scale, round 2 participants were then
asked to rerate each outcome taking into
consideration their own initial response
and the responses from the separate
stakeholder groups. At this point, par-
ticipants were also asked whether they
would be able and willing to attend a
subsequent planned face-to-face
consensus meeting. Only those partici-
pants who had completed rounds 1 and 2
were invited to participate in round 3.
In round 3, survey participants were
presented with outcomes from round 2
that were rated as important for inclu-
sion, deﬁned as scoring 7e9 on Likert
scale by at least 70% of all respondents
and rated as of limited importance (1e3
on Likert scale) by 15% of all re-
spondents. These consensus criteria for
round 3 were decided a priori based on
the total number of outcomes that
remained after round 2 and on guidance
in the COMET Handbook13 and COS-
STAD.11
After round 3, outcomes were then
classiﬁed as “consensus in” (70% par-
ticipants scoring as 7e9 and <15%
scoring as 1e3), “consensus out” (70%
scoring as 1e3 and <15% scoring as
7e9) or “no consensus” (anything else).
We agreed our consensus criteria for
inclusion a priori based on guidance in
the COMET Handbook13 and COS-
STAD.11
Consensus meeting
Consensus on the ﬁnal outcomes to be
included in the COS was achievedthrough a face-to-face full-day meeting
on April 18, 2018, in Brighton, UK. The
meeting was moderated by an inde-
pendent chair (J.K.), and the consensus
panel comprised 16 participants, from a
variety of countries, who represented
the stakeholder members who had
volunteered in their Delphi survey or
who had been sampled purposefully for
their expertise by the COSGROVE
working group. They were maternity
service users (n¼6), healthcare pro-
viders (midwives, obstetricians, neo-
natologists and family physicians;
n¼5), and researchers/academics in
FGR (n¼5). After a period of discus-
sion on each listed outcome, all par-
ticipants were asked to vote on each
outcome as “yes” or “no” for inclusion
in the ﬁnal COS. The consensus crite-
rion that was used at the meeting to
determine whether an outcome should
be in the ﬁnal COS was deﬁned as
70% of the consensus meeting par-
ticipants scoring it “yes.” The partici-
pants were also asked to consider
whether each outcome was uniquely a
prevention outcome, uniquely a treat-
ment outcome, or an outcome for both
prevention and treatment. Anonymous
voting was facilitated by participants
using Poll Everywhere (www.
polleverywhere.com). Members of the
COSGROVE working group attended as
observers only.
Results
The review of the literature identiﬁed
238 different outcomes for the preven-
tion and treatment of FGR.14 After the
removal of duplicate outcomes, the
combination of similar outcomes and
the clariﬁcation of outcome terminol-
ogy by the COSGROVE team, 103
outcomes remained. For example, cord
pH arterial, cord PO2 arterial, cord
PCO2 arterial, cord BE arterial, cord pH
venous, cord PO2 venous, cord PCO2
venous, and cord lactate all became the
outcome “umbilical cord blood gases.”
Grouping different outcome assess-
ments into a single category that
refers to an outcome in this manner is
recommended in the COMET Hand-
book,13 as is the subsequent classiﬁca-
tion of those outcomes underOCTOBER 2019 Amerioverarching domains. We considered
using the taxonomy of outcomes dis-
cussed by Dodd et al15 but found that
the domains maternal, fetal, neonatal,
childhood, and patient-reported, with
appropriate subdomains, were more
appropriate to our needs. Because there
was signiﬁcant overlap in the outcomes
for prevention and treatment, we
decided to present the 103 outcomes
(Supplementary Table 1) twice in the
round 1 Delphi survey; participants
were asked to rate them from a pre-
vention perspective ﬁrst and then from
a treatment perspective.
Two hundred thirty-eight relevant
stakeholders from 36 different coun-
tries registered to participate in COS-
GROVE and received the ﬁrst survey.
The round 1 survey was completed by
180 people (76%), of whom 59%
(n¼105) were healthcare providers,
29% (n¼53) were researchers/aca-
demics, and 12% (n¼22) were mater-
nity service users.
The round 2 survey again presented
the 103 outcomes twice. Some new
outcomes had been suggested by par-
ticipants in round 1. After evaluation,
these were all judged to be either covered
by the outcomes presented already or
suggested by 1 person only; therefore, in
keeping with the a priori decisions in the
study protocol,10 no new outcomes were
added after round 1. Round 2 was
completed by 65% (118/180) of those
who had completed the ﬁrst survey: 58%
healthcare providers (n¼69), 36% re-
searchers/academics (n¼42), and 6%
maternity service users (n¼7). At the
end of round 2, the number of outcomes
was reduced by applying our pre-
speciﬁed consensus criteria.
The round 3 survey presented 34
prevention outcomes and 35 treatment
outcomes for rating. Round 3 was
completed by 91% of those who had
completed the second survey (107/118).
The stakeholder groups represented in
the 3rd round were 59% (n¼63)
healthcare providers, 35% (n¼37) re-
searchers/academics, and 6% (n¼7)
maternity service users. At the end of
round 3, we again applied a priori
consensus criteria to decide which
outcomes to bring forward to thecan Journal of Obstetrics& Gynecology 339.e3
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outcomemet the criteria for “consensus
out,” 34 prevention outcomes and 35
treatment outcomes were brought for-
ward for discussion at the face-to-face
consensus meeting.
After the consensus meeting, 22 out-
comes were included in the ﬁnal COS for
the treatment or prevention of FGR
under 4 domains: maternal (n¼4); fetal
(n¼1); neonatal (n¼12), and childhood
(n ¼ 5). Given almost complete overlap,
the consensus panel participants
concluded that all 22 outcomes were
suitable for both prevention and treat-
ment; consequently, a single COS for the
prevention and/or treatment of FGR was
determined (Table). Outcomes that were
removed or combined after discussion339.e4 American Journal of Obstetrics& Gynecol(eg, stillbirth and intrapartum death
were combined into stillbirth) are listed
in Supplementary Table 2.
Comment
Main findings
COSGROVE developed a COS for FGR
with robust consensus methods to cap-
ture the views and opinions of an inter-
national group of multiple stakeholders
that included patients. The ﬁnal COS
includes 22 outcomes grouped under 4
domains. It is important that a COS
represents the minimum number of
outcomes that should be reported in all
trials in a speciﬁc area. The list is not
exhaustive, and additional outcomes can
be reported freely if deemed relevant.9
The list is suitable not only for trialsogy OCTOBER 2019but also for cohort studies, studies of
diagnostic accuracy, or service
evaluation.
Our effort was an international
collaboration between research groups
that aimed to standardize research,
monitoring, and management for FGR.
There is a growing recognition of the
need for standardizing outcome sets for
trials.11,16,17 Although there is an exten-
sive list of planned/ongoing and
completed COS in the health area of
“pregnancy and childbirth” on the
COMETwebsite (www.comet-initiative.
org/studies/search), there is currently
no published COS for FGR. This study
ﬁlls that deﬁcit. Effective dissemination
will now be required to ensure the up-
take of the COS. Dissemination through
the Core Outcomes in Women’s and
Newborn Health initiative will enable us
to disseminate widely to the relevant
community.17 We hope that our COS for
FGR will be adopted into future clinical
trials with the ultimate goal of informing
clinical practice.
The number of survey rounds varies
across COS development procedures,
with most containing 2 or 3 rounds.18
We decided to have 3 rounds because
of the number of outcomes presented
and believe that this number of iterations
was necessary.
Although the modiﬁed Delphi process
allowed participants to consider the
importance of the outcomes indepen-
dently, the consensus meeting provided
an opportunity for collaborative discus-
sion to reach consensus on the out-
comes. The equal representation of
stakeholder groups across the partici-
pants ensured that the meeting was
collaborative and inclusive and that the
voice of the public was not over-
shadowed by that of research academics
and practitioners; anonymous electronic
voting was used. Participants were
measured and reasonable in searching
for acceptable compromises to reach
consensus.
Strengths and limitations
We used COMET guidance to inform
our methods choices when developing
this COS.13,19 The process that was used
ajog.org OBSTETRICS Original Research(literature review, modiﬁed Delphi
survey, and consensus meeting) is a
well-established and widely used
consensus process. However, we do
acknowledge that methods to develop
COS vary20 and that there are limita-
tions in the evidence underlying the
method. For example, no validation
step is recommended in the process to
ask the stakeholders who completed
round 3 whether they agree or not with
the ﬁnal COS.
The initial long list of outcomes
presented in the survey was derived
from a comprehensive search of the
relevant literature. We adhered to
standard systematic searching and se-
lection strategies. We limited our
search to published clinical trials and
systematic reviews of trials because our
timelines did not allow review of
qualitative research studies. In addi-
tion, we included only English lan-
guage papers because we did not have
the resources for translating non-
English papers. However, we believe
that, given the large number of papers
reviewed and the large international
panel of participants who were able to
add outcomes as part of the open
questions of the survey, the likelihood
of missing relevant outcomes is very
small. The fact that no additional
outcomes were added to round 2
strengthened the value of this
approach. We acknowledge these
pragmatic decisions as potential
limitations.
We identiﬁed key stakeholders to cap-
ture a representative and diverse range of
opinions. This is important to ensure that
the outcomes that were included in the
resulting COS are relevant, applicable,
important, and acceptable to those
affected by FGR.21e24 Inclusion of
members of the public presents unique
challenges25; so, although an acceptable
number of maternity service users
initially registered to take part, a relatively
small number completed all 3 rounds of
the survey. However, their contribution
was rich, generous, insightful, and very
well-informed, and they were equally and
fairly represented at the consensus
meeting. We are convinced, after our
engagement with members of the public,that their involvement in COSGROVE
was meaningful, important, and relevant.
Another aspect of diversity is ensuring
geographic representation. It is recog-
nized that internationally developed core
outcome sets have more validity and are
easier to implement into clinical research
worldwide.9 Because of this, we were not
only mindful of the total number of
participants13,26 but also were ensured of
a “global” coverage of opinions.
Interpretation
The ﬁnal COS contains 22 outcomes to
be measured in all future trials in FGR.
We acknowledge that, considering that
this is a minimum amount of outcomes
to be reported, it may be considered
excessive. This is an unavoidable feature
of this particular clinical area that rep-
resents outcomes for both mother and
baby. This is consistent with other core
outcome sets in women’s and newborn
health, with outcome numbers varying
considerably from 11e48.20 The out-
comes are divided into a more
manageable number within the
maternal, fetal, neonatal, and childhood
domains. In addition, many of the
outcomes are overlapping. For example,
gestational age, preterm birth, and
extremely preterm birth are reported
separately. This reﬂects the independent
importance of the distribution of
gestational age in a study population
and also the proportion of preterm (or
extremely preterm) births. This is an
example of an easy win; these pro-
portions not only can be calculated
readily by researchers of primary
studies but also are impossible to work
out without access to individual data.
By reporting them in primary studies,
data synthesis is facilitated enormously.
There is also overlap between outcomes
and baseline characteristics. As an
example, preeclampsia may be a base-
line characteristic in 1 study and an
outcome in the same study or another.
This is reﬂected, indeed, by the fact that
hypertensive disorders of pregnancy are
also in the previously deﬁnedMinimum
Reporting Set.8 Obviously, different
interventions (eg, early delivery) may
also reduce the coappearance of pre-
eclampsia and its morbidities.OCTOBER 2019 AmeriLong-term follow-up outcomes
included in this COS may present difﬁ-
culties for some trials. However, the
consensus was that studies must
examine not only short-term neonatal
outcomes but also long-term develop-
ment.27 It is notable that most research
funding is limited to 2- to 3-year pro-
grams; in perinatal health, this is
incompatible with best practice (eg,
measuring childhood outcomes after
interventions given in early pregnancy
means a longer term approach is
needed). We hope that the views
expressed by our international group of
stakeholders will translate into research
practice by encouraging funders to look
beyond the short-term and allow for the
design of trials that ensure long-term
follow up, even if these are not re-
ported on in the initial publications. A
good example of this is the TRUFFLE
(The Trial of Randomized Umbilical and
Fetal Flow in Europe) trial in which
initial short-term outcomes were pub-
lished as a cohort and the primary
outcome of long-term follow up when
this became available later.28,29
COSGROVE has been developed to
guide researchers on what to measure;
however, it does not tell researchers how
to measure or when to measure, and
further work will be required to deter-
mine the most appropriate approach.
We acknowledge that there may be out-
comes in our COS that require further
research work around broader deﬁni-
tions. Some of the outcomes are well-
deﬁned in the literature and have a rec-
ognised method on “how” to measure
(eg, hypoxic ischemic encephalopathy
staging), although others do not (eg,
need for resuscitation).
Conclusion
International research collaboration is
needed to achieve progress in the
improvement of outcomes of mothers
and their children. Although adverse
outcomes in pregnancy are catastrophic,
they are fortunately rare. This means
that studies need to be large; data syn-
thesis of individual trials is a key
component needed to advance our ﬁeld.
This challenge can only be met if there is
agreement and standardization ofcan Journal of Obstetrics& Gynecology 339.e5
Original Research OBSTETRICS ajog.orgdeﬁnitions, exposures, and outcomes.
We have gathered an international group
of stakeholders to agree on and stan-
dardize the core set of outcomes that, as a
minimum, should be collected in all
future trials in FGR. We call on funders,
researchers, and the scientiﬁc commu-
nity to adopt COSGROVE into future
clinical trials in FGR with the ultimate
goal of improving health outcomes. n
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SUPPLEMENTARY TABLE 1
Fetal growth restriction outcomes presented in the Delphi Survey
Domain Outcome
1: Maternal
1.1: Maternal disease pregnancy related Pregnancy (gestational) hypertension
Preeclampsia




Development of thrombotic disease
Abnormal uterine artery Doppler scan
Placental abruption
1.2: Maternal care needs Admission to high dependency unit or intensive care
unit
Length of hospital stay
Cost of hospital stay
Days from diagnosis to delivery
1.3: Maternal delivery outcome Induction of labor
Mode of birth
Maternal death
1.4: Maternal postpartum outcome Postpartum hemorrhage
Postpartum infection
1.5: Maternal biochemical value Abnormal serum biomarkers (eg, antigenic factors,
placental growth factor, human chorionic
gonadotropin, pregnancy-associated plasma protein-
A)
1.6: Placental finding Placental weight
Abnormal placental histologic condition
Birthweight: placental weight ratio
2: Fetal/neonatal
2.1: Fetal ultrasound finding Abnormal biophysical profile score
Abnormal fetal Doppler assessment
Oligohydramnios
2.2: Fetal outcome Abnormal fetal scalp pH in labor
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SUPPLEMENTARY TABLE 1
Fetal growth restriction outcomes presented in the Delphi Survey (continued)
Domain Outcome
2.3: Neonatal birth outcome Livebirth
Apgar score at 5 minutes
Apgar score at 10 minutes
Abnormal umbilical cord blood gases
Gestational age at birth
Preterm birth (delivery at <37 weeks gestation)











Growth restriction of the newborn infant
2.4: Neonatal care outcome Length of hospital stay
Admission to high dependency or intensive care unit
Length of high dependency or intensive care unit stay
Cost of hospital stay
Readmission after discharge home
2.5: Neonatal immediate and short-term outcome Need for neonatal resuscitation
Need for any noninvasive respiratory support
Intubation
Need for mechanical ventilation
Need for surfactant
Respiratory distress syndrome






Need for therapeutic hypothermia (cooling)
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SUPPLEMENTARY TABLE 1






Feeding difficulties that require supplemental enteral
feeding
Feeding difficulties that require supplemental
parenteral feeding
Circulatory dysfunction that requires pressor support
Hypothyroidism that requires substitution treatment
Discharge weight









Childhood fat mass/body composition
Bayley Scales of infant development
2.7: Neonatal neurologic developmental outcome Cognitive impairment








3: Patient-reported outcome Maternal satisfaction with care
Difficulties in maternal and child bonding
Maternal posttraumatic stress disorder
Maternal depression
Maternal anxiety
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SUPPLEMENTARY TABLE 2
Outcomes removed or combined at the consensus meeting
Domain Outcome
Maternal HELLP (hemolysis, elevated liver enzymes, and low
platelet count) syndrome
Fetal Abnormal fetal Doppler assessment
Intrapartum death (combined with stillbirth)
Neonatal Umbilical cord blood gases
Apgar score at 5 minutes
Admission to high dependency or intensive care unit
Birthweight <5th percentile
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